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Objective: To establish outcome and optimal timing of local control
for patients with nonmetastatic Ewing sarcoma/primitive neuroec-
todermal tumor (ES/PNET) of the chest wall.
Methods: Patients 30 years of age with ES/PNET of the chest
wall were entered in 2 consecutive protocols. Therapy included
multiagent chemotherapy; local control was achieved by resection,
radiotherapy, or both. We compared completeness of resection and
disease-free survival in patients undergoing initial surgical resection
versus those treated with neoadjuvant chemotherapy followed by
resection, radiotherapy, or both. Patients with a positive surgical
margin received radiotherapy.
Results: Ninety-eight (11.3%) of 869 patients had primary tumors
of the chest wall. Median follow-up was 3.47 years and 5-year
event-free survival was 56% for the chest wall lesions. Ten of 20
(50%) initial resections resulted in negative margins compared with
41 of 53 (77%) negative margins with delayed resections after
chemotherapy (P  0.043). Event-free survival did not differ by
timing of surgery (P  0.69) or type of local control (P  0.17).
Initial chemotherapy decreased the percentage of patients needing
radiation therapy. Seventeen of 24 patients (70.8%) with initial
surgery received radiotherapy compared with 34 of 71 patients
(47.9%) who started with chemotherapy (P  0.061). If a delayed
operation was performed, excluding those patients who received
only radiotherapy for local control, only 25 of 62 patients needed
radiotherapy (40.3%; P  0.016).
Conclusion: The likelihood of complete tumor resection with a
negative microscopic margin and consequent avoidance of external
beam radiation and its potential complications is increased with
neoadjuvant chemotherapy and delayed resection of chest wall
ES/PNET.
(Ann Surg 2003;238: 563–568)
Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) is the most frequent malignant tumor of the chest
wall in children and young adults. It is an aggressive tumor in
which distant micrometastasis must be assumed to be present,
and all patients receive adjuvant chemotherapy to control the
distant disease. One major clinical decision at presentation of
ES/PNET of the chest wall is whether to resect the primary
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tumor initially or after neoadjuvant chemotherapy. Complete
resection is the goal, and if this is accomplished with ade-
quate margins, it allows the patient to avoid radiation therapy
with its potential long-term complications, including pulmo-
nary fibrosis, an increased incidence of coronary artery dis-
ease, and a significant incidence of secondary tumors.1–4 A
previous analysis of the first protocol in this study suggested
that initial treatment with adjuvant chemotherapy might in-
crease the frequency of complete resection of the tumor and
result in a decreased need for radiotherapy to the chest.5 We
repeated this analysis for the combined protocols to both
increase the number of subjects available for review as well
as to extend the interval of follow-up.
MATERIALS AND METHODS
Patient Population and Therapeutic Plan
The initial study (INT-0091) was open for enrollment
from December 1988 to November 1992. The subsequent
study (POG 9354) was open from May 1995 to September
1998. Eligibility required an age of 30 years or less at
diagnosis and a tumor with the histologic diagnosis of Ewing
sarcoma or primitive neuroectodermal tumor. The initial
study limited enrollment to patients with tumors of bone, and
included metastatic patients. The second study (POG 9354)
included patients with tumors of soft tissue as well as those of
bone, but excluded patients with documented metastases at
diagnosis. All tumors received central pathology review and
confirmation of diagnosis. The current analysis reviews the
records of nonmetastatic patients only from both intergroup
protocols. Patients who received chemotherapy and/or radia-
tion therapy prior to diagnosis and study registration were
excluded. Eligibility required the initiation of protocol che-
motherapy within 1 month of the diagnostic biopsy. Informed
written consent according to institutional guidelines was
required prior to study entry.
In each study patients were randomized at study entry
to receive 1 of 2 chemotherapy treatments. Patients in INT-
0091 were randomized to receive either the then standard
regimen of vincristine, cyclophosphamide, and doxorubicin
(or actinomycin-D) or the standard regimen alternating by
course with courses of ifosfamide and etoposide. The group
that received ifosfamide and etoposide had a better outcome,
and thus that regimen served as the standard arm of the
second protocol.6 The experimental therapy for the subse-
quent protocol employed the same chemotherapeutic agents
and the same total doses as the standard arm, but delivered
them in a dose intensified manner. Details of the chemother-
apy regimens are presented elsewhere.6,7
Local control measures consisted of either radiation
therapy, an operation, or both; physicians at treating institu-
tions decided on local control methods for each patient. Local
control was to occur at 12 weeks, and surgery was allowed
for tumors deemed to be resectable. For patients who did not
have resection attempts, radiotherapy ports included the ini-
tial tumor volume (soft tissue and osseous extent of tumor)
with a 3-cm margin to 4500 cGy followed by a reduction of
the port to the postchemotherapy, preradiotherapy extent of
tumor for an additional 1080 cGy. The total dose was 5580
cGy. Guidelines for radiation therapy were the same for
patients with gross residual disease after surgery. If only
microscopic disease remained after surgery, the total dose
was 5040 cGy with a 1-cm margin of the initial tumor
volume. The protocol allowed for attempted surgical resec-
tion before the start of chemotherapy.
Statistical Analysis
Event-free survival was defined as the time from study
entry until disease progression, diagnosis of a second malig-
nant neoplasm, or death. Otherwise, the patient was censored
at the date of last contact. For INT-0091, data were current as
of 8/31/00 for CCG patients, and 8/21/02 for POG patients.
For POG 9354 patients, data were current as of 8/20/02.
For a patient to be considered eligible for evaluation for
local control, the individual must have started maintenance
after all local interventions were completed. Event-free sur-
vival after local control was defined to be the time from the
start of maintenance therapy until disease progression, diag-
nosis of a second malignant neoplasm, or death whichever
came first. Otherwise, the patient was censored at the date of
last contact. The log-rank test was used to determine which
factors were independently prognostic for outcome.
The standard errors of the Kaplan-Meier-product-limit
survival estimates, were computed using the method of Peto
et al.8 Risk for adverse event was compared across groups
using the log-rank test.9 The Fisher exact test was used to test
for association between pairs of categorical variables.
RESULTS
Ninety-eight (11.3%) of 869 patients enrolled in these 2
protocols had primary chest wall tumors (INT-0091: 53 of
393 patients and POG 9354: 45 of 476 patients). Median
follow-up time for patients with chest wall lesions was 3.47
years. The 5-year event-free survival was 56% (SE 7%) for
the chest wall lesions compared with 64% (SE 2.4%) for the
entire cohort of patients. Patients with primary lesions of the
chest wall achieved an event-free survival equivalent to that
of patients with primary lesions of the humerus/femur and
pelvis (P  0.26), but patients with primary lesions of the
distal extremities or soft tissue had better event-free survival
(P  0.025; Fig. 1).
Tumor resection was attempted in 25 patients before
the start of chemotherapy. In the initial study 16 of 53
patients had an initial resection. In the second study 9 of 45
patients had a primary resection (P  0.35). The size of the
primary tumor (largest dimension 8 cm or 8 cm) did not
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appear to effect whether patients were managed with primary
resection versus adjuvant chemotherapy with delayed resec-
tion (P  0.26).
Three patients were not evaluatable for local control.
One patient developed progressive disease during the local
control interval, the second developed progressive disease at
week 25, and the third went off study at week 20 when further
treatment was refused, all before they entered the mainte-
nance phase of therapy.
Margins as assessed by the institutional pathologists
were available for 20 of 25 patients with primary resection
and 53 of 62 delayed resections performed after initial treat-
ment with chemotherapy. Ten of 20 (50%) initial resections
resulted in negative margins compared with 41 of 53 (77%)
delayed resections after chemotherapy (P  0.043). Seven-
teen of 24 patients (70.8%) with initial surgery received
radiotherapy compared with 34 of 71 patients (47.9%) who
started with chemotherapy (P  0.061).
We attempted to exclude patients for whom surgery
was not an option, thus eliminating patients who would
always need radiation independent of timing of local control,
such as those with apical or spinal extensions. We assumed
that anyone who could have a surgical excision had surgery
either upfront or after induction chemotherapy. Only patients
who had a resection (either primary or after chemotherapy)
were included in the analyses. Nine patients who had only
radiotherapy for local control were excluded. Only 25 of 62
patients (40.3%) who had delayed operations needed radia-
tion therapy, a lower proportion compared with those patients
who had primary resections (P  0.016).
Event-free survival did not differ by timing of surgery
computed as time elapsed from date of resection (P  0.69;
Fig. 2) or type of local control (P  0.17; Fig. 3). The local
recurrence rate did not depend on the type of local control
(P  0.95), but the number of patients and the frequency of
events was small. Similarly, event-free survival for patients
with tumor free pathologic margins did not differ between
patients whose local control was surgery alone and those who
had surgery and radiotherapy (P  0.97; Fig. 4); however,
sample sizes were small (31 had surgery alone, and 18 had
surgery and radiotherapy).
DISCUSSION
Complete resection of the primary tumor of the chest
wall was accomplished more frequently in resections per-
formed after initial adjuvant chemotherapy compared with
primary resections. Although thoracic tumors are frequently
large and similar to the size of tumors of the pelvis, a primary
resection is often attempted for chest wall lesions while
secondary resection is generally the approach for tumors of
this size at other sites.5 The probability of initial resection
attempt was independent of tumor size in this study. Delayed
resection resulted in a significant decrease in the proportion
of patients requiring radiation therapy to the chest. Radiation
therapy in doses recommended for the treatment of Ewing
FIGURE 1. Kaplan-Meier estimate of event-free survival for
patients according to site of primary tumor: ribs (n  98),
humerus or femur (n  188), pelvis (n  159), and all other
sites (n  424). No difference was seen between the rib, pelvis
and humerus/femur cohorts (P  0.26), but a clear difference
existed between the “other” lesions when compared with rib
(P  0.01), pelvis (P  0.01), and humerus/femur (P  0.02)
cohorts.
FIGURE 2. Kaplan-Meier estimate of event-free survival for
patients shown according to whether they had primary resec-
tion or post chemotherapy resection (P  0.69).
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sarcoma/PNET has been associated with a significant inci-
dence of secondary tumors in these patients (10–30%).1–4
Furthermore, radiation therapy to the thorax causes specific
and significant toxicity: pulmonary fibrosis may occur if large
volumes of lung are in the radiation field.10,11 Radiation to the
heart increases the likelihood for doxorubicin induced car-
diomyopathy, and patients with Hodgkin disease have devel-
oped coronary artery disease from radiation to their heart at
significantly lower doses than received for this disease.12,13
We found no survival benefit caused by primary resec-
tion of the tumor. However, patients undergoing definitive
surgery after initial chemotherapy had a higher frequency of
successful complete resection of the tumor, eventuating in the
avoidance of radiation therapy to the chest. These findings
lead us to agree with others who have concluded based on
much smaller series that the preferred sequence of therapy for
these patients is initial biopsy followed by adjuvant chemo-
therapy with delayed resection after 4 courses of treat-
ment.5,14–16 This will not avoid the need for radiation in all
patients, particularly those with paravertebral or apical in-
volvement or those with extremely large tumors. But in the
majority of patients, adjuvant chemotherapy will significantly
shrink the tumor as well as decrease its friability and vascu-
larity, which will enhance the surgeon’s ability to define the
margins of the lesion and achieve its complete resection. The
data showed no benefit caused by the addition of radiotherapy
to the local control of patients with complete resection and
pathologic margins free of tumor, however the number of
patients in this analysis who had surgery and radiotherapy
was small.
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Discussion
DR. RICHARD J. ANDRASSY (Houston, Texas): Dr. Sham-
berger and his colleagues have reported their results from 2
consecutive cooperative trials on the management of chest
wall small round cell tumors, specifically Ewing’s sarcoma/
primitive neural ectodermal tumors. Chest wall sites have
continued to have a poorer prognosis than other sites, but
recent changes in neoadjuvant chemotherapy provide some
hope of improved outcome.
The hypothesis of this review is that neoadjuvant che-
motherapy followed by resection would result in better local
control and decreased distant relapse compared with primary
surgery followed by chemo and/or radiation. They did show
that the number of patients achieving negative margins im-
proved in the patients receiving neoadjuvant therapy.
Although my bias is to provide neoadjuvant therapy
and then resection, the results of this study do not provide a
statistical difference in that event-free survival and local
recurrence were no different in the group receiving neoadju-
vant therapy or primary resection. The number of patients in
the neoadjuvant group receiving postoperative radiation was
reduced, which is admirable in light of the complications of
radiation in children. I have 2 questions.
Number 1, even though you didn’t see much difference
in the size of the tumor between the group receiving radiation
and the group not receiving radiation, is it possible that the
group receiving radiation had more involved or extensive
tumors and despite that they had the same incidence of local
control? Is it possible that patients with reportedly negative
margins may have had less local recurrence if they were
radiated as well?
Number 2, some authors, including Rao and others,
have stated that neoadjuvant chemotherapy allows the sur-
geon to remove only the involved rib and that a chest wall
resection is not necessary for local control. It appears that
many patients in this study had a more formal chest wall
resection. What is your recommendation for the extent of
resection?
Thank you for your continued interest in this group of
difficult patients and your fine presentation. Thank you.
DR. ROBERT C. SHAMBERGER (Boston, Massachusetts):
Thank you, Dr. Andrassy, for your kind comments. In re-
sponse to the first question, we did an analysis to look at the
size of the tumors included in the primary resection and
secondary resection groups. We found, surprisingly enough,
that there was an equal frequency of large lesions in both
groups. We could not demonstrate a preference for preoper-
ative chemotherapy in the patients with large tumors. This
was well-demonstrated, however, in the extremity lesions
treated primarily by our orthopedic colleagues. We found no
basis for the administration of radiotherapy to patients who
had completely negative resection margins. In searching
through the literature, we could find no evidence to support
this widely prevalent practice.
In response to the question regarding what extent of
resection is necessary, we follow the policy that you must
resect anything that looks like residual or scarred tumor. In
the very fibrotic tissue resulting from chemotherapy you can
have microscopic islands of residual tumor demonstrated.
There was an effort by St. Jude’s Children’s Research
Hospital reported by Arai to decrease the dose of radiation in
patients who had a very good response to chemotherapy.
They decreased dosage to 30 to 36 Gy. They had a marked
increase in the local recurrence rate to 38% within the
radiation field, which has led us to believe that despite the
apparent efficacy of chemotherapy, you cannot decrease the
extent of local control measures.
DR. MURRAY F. BRENNAN (New York, New York): Is
that true, Dr. Shamberger? Does local recurrence change
survival?
DR. ROBERT C. SHAMBERGER (Boston, Massachusetts):
In both of these protocols patients who have suffered local
relapse have done poorly. They have been treated with all of
the known effective agents, so have very few therapeutic
options.
DR. MURRAY F. BRENNAN (New York, New York):
Distant relapse kills you. That is true. Metastasis kills pa-
tients. Does local recurrence kill patients?
DR. ROBERT C. SHAMBERGER (Boston, Massachusetts):
Local recurrence has been a very unfavorable prognostic
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indicator. Of 10 patients with local relapse, 9 have died
including all 6 who initially had only local recurrence.
DR. MURRAY F. BRENNAN (New York, New York): That
is not the question I asked. Local recurrence is a very bad
factor, but is it a cause of death?
DR. ROBERT C. SHAMBERGER (Boston, Massachusetts): Yes.
DR. MURRAY F. BRENNAN (New York, New York):
Some of us might disagree about that.
DR. ROBERT C. SHAMBERGER (Boston, Massachusetts): If
you have local recurrence and you are not able to control the
local recurrence in those cases, that leads to metastatic dis-
ease. The recurrent tumor is often not resectable.
DR. MURRAY F. BRENNAN (New York, New York):
Uncontrolled local recurrence causes death. I accept that.
DR. LUIS O. VASCONEZ (Birmingham, Alabama): May I
ask Dr. Shamberger a question? On the patients who received
neoadjuvant chemotherapy, what was the interval of time
between the chemotherapy and institution of surgery, and
have you had any delayed wound healing problems for such
patients?
DR. ROBERT C. SHAMBERGER (Boston, Massachusetts):
Administering chemotherapy within a 7 to 10 day period of a
surgical incision in an experimental model produces a signif-
icant impairment in wound healing. The agents administered
determine the extent of impairment, but Adriamycin produces
1 of the greatest adverse impacts. In this study, the compli-
cations of the primary and secondary surgical resections were
limited and no significant difference in complications could
be demonstrated between the 2 cohorts.
DR. THOMAS R. WEBER (St. Louis, Missouri): Dr. Sham-
berger, you mentioned second malignancies early in your
presentation. Did any of these patients have second malig-
nancies, and were they the cause of death in any of them?
DR. ROBERT C. SHAMBERGER (Boston, Massachusetts):
In these protocols there have been second malignancies that
have occurred, Dr. Weber. I do not believe any have occurred
in the patients with chest wall primaries. Second malignan-
cies generally first appear between three-and-a-half and 5
years after exposure, so we are still relatively early in the
follow-up interval for these complications. We have been
unable, as Dr. Andrassy pointed out, to show increased
survival for patients with complete resection in our current
studies. We are fearful, however, that patients who have
received radiation in the thorax as part of their therapy will
over the long term have significant morbidity and mortality,
particularly cardiomyopathy from the combination of Adria-
mycin and irradiation of the heart. Alkalating agents are
associated with secondary tumors, and the addition of radia-
tion therapy, particularly at doses above 4,000 cGy signifi-
cantly increases the incidence of second malignancies.
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